Internet pharmaco-economic studies in metastatic colorectal cancer
An interactive Web site has been developed: http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic colorectal cancer. This site allows drug usage costs, daily tariff costs per site, local ISA point values and the cost to the society of the chemo...
Saved in:
Published in | Critical reviews in oncology/hematology Vol. 38; no. 1; pp. 63 - 77 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
01.04.2001
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | An interactive Web site has been developed:
http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic colorectal cancer. This site allows drug usage costs, daily tariff costs per site, local ISA point values and the cost to the society of the chemotherapies prescribed to be recorded by cycle in a de-centralised manner. The overall cost of treatment may be calculated by one of these four units from the time when the first chemotherapy was administered until the patient has escaped from first or second line treatment. The median time to progression and the median survival time are key parameters used to calculate costs as they determine the number of patients who remain on treatment, course by course. Effectiveness results have been measured in terms of progression free survival or of global survival. Eight treatment strategies have been examined. It is possible to add new treatment regimens or new compounds into the existing pre-formatted tables. This software enables budgets to be planned depending on the regimen used and the number of patients treated. It also allows the different treatment options to be classified with respect to their incremental cost effectiveness ratio, which is defined by the additional cost of one treatment option compared to another divided by the corresponding increase in effectiveness. |
---|---|
AbstractList | An interactive Web site has been developed: http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic colorectal cancer. This site allows drug usage costs, daily tariff costs per site, local ISA point values and the cost to the society of the chemotherapies prescribed to be recorded by cycle in a de-centralised manner. The overall cost of treatment may be calculated by one of these four units from the time when the first chemotherapy was administered until the patient has escaped from first or second line treatment. The median time to progression and the median survival time are key parameters used to calculate costs as they determine the number of patients who remain on treatment, course by course. Effectiveness results have been measured in terms of progression free survival or of global survival. Eight treatment strategies have been examined. It is possible to add new treatment regimens or new compounds into the existing pre-formatted tables. This software enables budgets to be planned depending on the regimen used and the number of patients treated. It also allows the different treatment options to be classified with respect to their incremental cost effectiveness ratio, which is defined by the additional cost of one treatment option compared to another divided by the corresponding increase in effectiveness. An interactive Web site has been developed: http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic colorectal cancer. This site allows drug usage costs, daily tariff costs per site, local ISA point values and the cost to the society of the chemotherapies prescribed to be recorded by cycle in a de-centralised manner. The overall cost of treatment may be calculated by one of these four units from the time when the first chemotherapy was administered until the patient has escaped from first or second line treatment. The median time to progression and the median survival time are key parameters used to calculate costs as they determine the number of patients who remain on treatment, course by course. Effectiveness results have been measured in terms of progression free survival or of global survival. Eight treatment strategies have been examined. It is possible to add new treatment regimens or new compounds into the existing pre-formatted tables. This software enables budgets to be planned depending on the regimen used and the number of patients treated. It also allows the different treatment options to be classified with respect to their incremental cost effectiveness ratio, which is defined by the additional cost of one treatment option compared to another divided by the corresponding increase in effectiveness. |
Author | Perrocheau, G. Launois, R. Portafax, C. Le Lay, K. Mègnigbêto, A. |
Author_xml | – sequence: 1 givenname: R. surname: Launois fullname: Launois, R. email: launois_ireme@smbh.univ-paris13.fr organization: Institut de recherche et d’évaluation médicale et économique, Université de Paris XIII, UFR SMBH 74, rue Marcel Cachin, 93017 Bobigny Cédex, France – sequence: 2 givenname: C. surname: Portafax fullname: Portafax, C. organization: Institut de recherche et d’évaluation médicale et économique, Université de Paris XIII, UFR SMBH 74, rue Marcel Cachin, 93017 Bobigny Cédex, France – sequence: 3 givenname: K. surname: Le Lay fullname: Le Lay, K. organization: Institut de recherche et d’évaluation médicale et économique, Université de Paris XIII, UFR SMBH 74, rue Marcel Cachin, 93017 Bobigny Cédex, France – sequence: 4 givenname: A. surname: Mègnigbêto fullname: Mègnigbêto, A. organization: Centre d'Evaluation Clinique René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain, France – sequence: 5 givenname: G. surname: Perrocheau fullname: Perrocheau, G. organization: Centre d'Evaluation Clinique René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain, France |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=996785$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11255082$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkEtLAzEQgIMoatWfoCwIoofVyT6yyUm0-CgIHuw9TLNTjOxuapIK_ntTW_UoDMwwfDPJfCO2PbiBGDvmcMmBi6sXDhXksirkOcAFAC_qXGyxfS4blUMl-Haqf5A9NgrhDQCqSjS7bI8nugZZ7LPbyRDJDxSzxSv6Ho3LybjB9dZkIS5bSyGzQ9ZTxBAxpq5xnfNkInaZwcGQP2Q7c-wCHW3yAZve303Hj_nT88NkfPOUm1KqmFcFlvMSqVAKpFFYVtjUvEDRGgEClWooESlmXCoupcG2xhKrFmSralkesLP12oV370sKUfc2GOo6HMgtg26EauoSRALrNWi8C8HTXC-87dF_ag565U5_u9MrMRpAf7vTq7mTzQPLWU_t39RGVgJONwAGg93cp_Nt-OWUEo2sE3W9pii5-LDkdTCWkqjWrrTp1tl_PvIFMeSMFA |
CitedBy_id | crossref_primary_10_1016_S0001_4079_19_33323_0 crossref_primary_10_1016_S0399_8320_05_82118_9 |
ContentType | Journal Article |
Copyright | 2001 Elsevier Science Ireland Ltd 2001 INIST-CNRS |
Copyright_xml | – notice: 2001 Elsevier Science Ireland Ltd – notice: 2001 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/S1040-8428(00)00125-6 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0461 |
EndPage | 77 |
ExternalDocumentID | 10_1016_S1040_8428_00_00125_6 11255082 996785 S1040842800001256 |
Genre | Meta-Analysis Journal Article Review |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29F 4.4 457 4CK 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABJNI ABLJU ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFS ACIUM ACRLP ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W KOM LCYCR M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SEL SES SEW SSH SSZ T5K UDS W2D WUQ Z5R ~G- ABPIF ABPTK IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c389t-42a3f3ae29908c9a34a7512a6dc606a997e2a32a3b189188cad5a3a4d08d9583 |
IEDL.DBID | AIKHN |
ISSN | 1040-8428 |
IngestDate | Fri Aug 16 02:41:00 EDT 2024 Thu Sep 26 18:42:18 EDT 2024 Sat Sep 28 07:35:59 EDT 2024 Sun Oct 22 16:07:32 EDT 2023 Fri Feb 23 02:33:20 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Regimens Cost effectiveness ratio Cost Budgetary forecast Metastatic colorectal cancer Antineoplastic agent Human Drug combination Rectal disease Malignant tumor Forecasting Colonic disease Chemotherapy Treatment Health economy Rectum Digestive diseases Intestinal disease Advanced stage Budget Colon Internet Therapeutic protocol Web site Public health Cost efficiency analysis |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c389t-42a3f3ae29908c9a34a7512a6dc606a997e2a32a3b189188cad5a3a4d08d9583 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
PMID | 11255082 |
PQID | 76975306 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_76975306 crossref_primary_10_1016_S1040_8428_00_00125_6 pubmed_primary_11255082 pascalfrancis_primary_996785 elsevier_sciencedirect_doi_10_1016_S1040_8428_00_00125_6 |
PublicationCentury | 2000 |
PublicationDate | 2001-04-01 |
PublicationDateYYYYMMDD | 2001-04-01 |
PublicationDate_xml | – month: 04 year: 2001 text: 2001-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Shannon |
PublicationPlace_xml | – name: Shannon – name: Netherlands |
PublicationTitle | Critical reviews in oncology/hematology |
PublicationTitleAlternate | Crit Rev Oncol Hematol |
PublicationYear | 2001 |
Publisher | Elsevier Ireland Ltd Elsevier Science |
Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier Science |
References | De Gramont, Vignoud, Tournigaud (BIB9) 1997; 18 Epstein Richard (BIB14) 1992; 28 Launois, Portafax, Perrocheau (BIB10) 1999; 112 Rougier, Van Cutsem, Bajetta (BIB7) 1998; 352 Douillard, Cunningham, Roth (BIB2) 2000; 355 De Gramont, Bosset, Milan (BIB1) 1997; 15 De Gramont, Vignoud, Tournigaud (BIB6) 1997; 33 Goldman (BIB17) 1990 Wasserman, Cuvier, Lokiec (BIB8) 1999; 17 De Gramont, Figer, Seymour (BIB3) 1998; 17 Maindrault Goebel, De Gramont, Louvet (BIB5) 1998; 17 Launois (BIB11) 1999; 17 Launois, Reboul-Marty (BIB13) 1994; 23 De Gramont, Louvet, Carola (BIB4) 1998; 17 Laupacis, Feeny, Detsky, Tugwell (BIB16) 1992; 146 Launois, Croutsche, Megnigbeto, Le Lay (BIB12) 1999; 17 Tengs, Adams, Pliskin (BIB15) 1995; 15 |
References_xml | – volume: 146 start-page: 473 year: 1992 end-page: 481 ident: BIB16 article-title: How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations publication-title: Can. Med. Assoc. J. contributor: fullname: Tugwell – volume: 18 start-page: 769 year: 1997 end-page: 775 ident: BIB9 article-title: Oxaliplatine, acide folinique et 5 fluorouracile en seconde ligne thérapeutique du cancer colorectal métastasé publication-title: Rev. Méd Int. contributor: fullname: Tournigaud – volume: 17 start-page: 1751 year: 1999 end-page: 1759 ident: BIB8 article-title: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics publication-title: J. Clin. Oncol. contributor: fullname: Lokiec – start-page: 11 year: 1990 end-page: 15 ident: BIB17 article-title: Cost awareness in medecine publication-title: Harrisson's Principles of Internal Medecine contributor: fullname: Goldman – volume: 17 start-page: 985 year: 1998 ident: BIB3 article-title: A randomized trial of leucovorin and 5 fluorouracil with or without oxaliplatin in advanced colorectal cancer publication-title: Proc. ASCO contributor: fullname: Seymour – volume: 17 start-page: 343 year: 1999 end-page: 361 ident: BIB12 article-title: L'apport indispensable de l'épidémiologie clinique aux modèles de Markov publication-title: J. d'Econ. Méd. contributor: fullname: Le Lay – volume: 28 start-page: 486 year: 1992 end-page: 492 ident: BIB14 article-title: Does the breast cancer dollar make sense? publication-title: Eur. J. Cancer contributor: fullname: Epstein Richard – volume: 17 start-page: 1048 year: 1998 ident: BIB5 article-title: Bi-monthly oxaliplatin with leucovorin and 5 fluorouracil in pretreated metastatic colorectal cancer (Folfox6) publication-title: Proc. ASCO contributor: fullname: Louvet – volume: 17 start-page: 77 year: 1999 end-page: 82 ident: BIB11 article-title: Un coût, des coûts, quels coûts? publication-title: J. d'Econ. Méd. contributor: fullname: Launois – volume: 355 start-page: 1041 year: 2000 end-page: 1047 ident: BIB2 article-title: Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomized trial publication-title: Lancet contributor: fullname: Roth – volume: 352 start-page: 1407 year: 1998 end-page: 1412 ident: BIB7 article-title: Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer publication-title: Lancet contributor: fullname: Bajetta – volume: 33 start-page: 214 year: 1997 end-page: 219 ident: BIB6 article-title: Oxaliplatin with High dose leucovorin and 5 fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer (folfox2) publication-title: Eur. J. Cancer contributor: fullname: Tournigaud – volume: 112 start-page: 18 year: 1999 end-page: 24 ident: BIB10 article-title: Cancer du côlon — Chimiothérapie de seconde ligne: les enjeux publication-title: Le Moniteur Hospitalier contributor: fullname: Perrocheau – volume: 17 start-page: 1049 year: 1998 ident: BIB4 article-title: Bi-monthly CPT11 with leucovorin and 5 fluorouracil in pretreated metastatic colorectal cancer (folfiri) publication-title: Proc. ASCO contributor: fullname: Carola – volume: 23 start-page: 170 year: 1994 end-page: 173 ident: BIB13 article-title: Coût-efficacité marginal: un outil de l’économiste publication-title: Cardioscopies contributor: fullname: Reboul-Marty – volume: 15 start-page: 808 year: 1997 end-page: 815 ident: BIB1 article-title: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer publication-title: J. Clin. Oncol. contributor: fullname: Milan – volume: 15 start-page: 369 year: 1995 end-page: 390 ident: BIB15 article-title: Five hundred life saving interventions and their cost-effectiveness publication-title: Analysis contributor: fullname: Pliskin |
SSID | ssj0004467 |
Score | 1.6806842 |
SecondaryResourceType | review_article |
Snippet | An interactive Web site has been developed:
http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic... An interactive Web site has been developed: http://smbh7.smbh.univ-paris13.fr, which uses a Markov model to calculate the management costs for metastatic... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 63 |
SubjectTerms | Antineoplastic agents Biological and medical sciences Budgetary forecast Chemotherapy Clinical Protocols Colorectal Neoplasms - drug therapy Colorectal Neoplasms - economics Colorectal Neoplasms - secondary Cost Cost effectiveness ratio Fees, Pharmaceutical Humans Internet - utilization Markov Chains Medical sciences Metastatic colorectal cancer Multicenter Studies as Topic - economics Multicenter Studies as Topic - methods Pharmacology. Drug treatments Regimens |
Title | Internet pharmaco-economic studies in metastatic colorectal cancer |
URI | https://dx.doi.org/10.1016/S1040-8428(00)00125-6 https://www.ncbi.nlm.nih.gov/pubmed/11255082 https://search.proquest.com/docview/76975306 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH_MCSKI-O387MGDHuLSJm3T4xTHVPTihN1C1qawg13Zuqt_uy9NurGDCEJPIXkJv6Tv95K89wJwkzNt3qJMCZq2nHAeRyRBFic0Y76vRJjT2onm7T0afPKXUThqwWMTC2PcKp3utzq91taupOvQ7JaTSfcDNxJUYBf1ATUy9wZsIh1x3obN3vPr4H0VHsnrh2RNfWIarAJ5rJC68JbSu1oOiX6jqJ1SzRG43L548btJWlNTfw92nU3p9eyw96GliwPYenO35ofwYI_9dOWVLlE10S4e2ZtbP0JvUnhfulImvghLTSprAwtKTc2ymB3BsP80fBwQ93YCSdEEqRB6xXKmtGEbkSaKcRUjt6soS3HLopIk1lgDv7EvEl-IVGWhYopnVGRJKNgxtItpoU_BE2gjJjxELs81R3pPmBJZEKQqYGlA87wD9w1asrQZMuTSdczAKw28kpo0pAivjDogGkzl2lRL1OJ_Nb1Ym4Nlh7hri0XYgetmSiT-JebqQxV6upjLODIBxBQFnNiZWg0VBaORGpz9f1TnsG0904w_zwW0q9lCX6KpUo2vYOP-279yC_IHsZHf_g |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwED6VIgESQrwpFJqBAQZTJ87DGaGiKtB2oUjdLDdxpA6kUZuu_HbOcdKqQ4WElMlKztZ3zn1n--4McJ8wpe-ijAi6ti5x3cAnIbI4oTGzbcm9hBZBNIOh3_ty38feuAadKhdGh1WWtt_Y9MJaly3tEs12Np22P3EhQTl2UWxQI3PvwK72BnRc19PPOs4D1zuBKUlAiX59ncZjRBSND5Q-FlKIv42gDjO5QNgSc9_Fdoe0IKbuMRyVHqX1bAZ9AjWVnsLeoDwzP4MXs-mncisry1QTVWYjWwsTRWhNU-tb5VJnF2GrLmStQUGpkZ4U83MYdV9HnR4pb04gETogOQIvWcKk0lzDo1AyVwbI7NKPI1ywyDAMFL6Bz8Tmoc15JGNPMunGlMehx9kF1NNZqq7A4ughhq6HTJ4oF8k9ZJLHjhNJh0UOTZIGPFVoiczUxxCrwDENr9DwCqqLkCK8wm8ArzAVG4oWaMP_-rS5oYNVh7hmC7jXgFalEoH_iD74kKmaLRci8HX6MEUBl0ZT66GiYHRRnev_j6oF-73RoC_6b8OPGzgwMWo6sqcJ9Xy-VLfotOSTu2JS_gKiluDT |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Internet+pharmaco-economic+studies+in+metastatic+colorectal+cancer&rft.jtitle=Critical+reviews+in+oncology%2Fhematology&rft.au=LAUNOIS%2C+R&rft.au=PORTAFAX%2C+C&rft.au=LE+LAY%2C+K&rft.au=MEGNIGBETO%2C+A&rft.date=2001-04-01&rft.pub=Elsevier+Science&rft.issn=1040-8428&rft.eissn=1879-0461&rft.volume=38&rft.issue=1&rft.spage=63&rft.epage=77&rft_id=info:doi/10.1016%2FS1040-8428%2800%2900125-6&rft.externalDBID=n%2Fa&rft.externalDocID=996785 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1040-8428&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1040-8428&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1040-8428&client=summon |